Company / Cost of Revenue
AVADEL PHARMACEUTICALS PLC Cost of Revenue History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$15.3M
FY2024
5-year range
$0 / $15.3M
FY2020-FY2024
Trend
+1705.8%
vs FY2023
Sector context
#68 of 85
Health Care
What the data says
Cost of Revenue changed +1706% YoY in FY2024, a notable deviation from the 7-year average annual change of +224%.
Based on SEC 10-K filings.
$15M in FY2024 with a 5-year CAGR of +4.7%.
Increased from $0 to $15M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +4.7%
- 10-Year CAGR
- -
Sector benchmark
Top 20% in Health CareTop 20% of 85This company $15.3M Sector average $2.0B
▼
-99.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +4.7%, indicating consistent growth.
- In FY2024, cost of revenue increased 1705.8% year-over-year.
- Ranks #68 out of 85 companies in the Health Care sector.
- Peak cost of revenue was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -28.9%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $15.3M | +1705.8% |
| FY2023 | $846.0K | - |
| FY2022 | $0 | - |
| FY2021 | $0 | -100.0% |
| FY2020 | $5.7M | -52.6% |
| FY2019 | $12.1M | -30.8% |
| FY2018 | $17.5M | +7.5% |
| FY2017 | $16.3M | +23.0% |
| FY2016 | $13.2M | +16.1% |
| FY2015 | $11.4M | +237.3% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026